|
US6020492A
(en)
|
1995-05-12 |
2000-02-01 |
Neurogen Corporation |
Deazapurine derivatives; a new class of CRF1 specific ligands
|
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
|
US6060478A
(en)
*
|
1996-07-24 |
2000-05-09 |
Dupont Pharmaceuticals |
Azolo triazines and pyrimidines
|
|
US6313124B1
(en)
|
1997-07-23 |
2001-11-06 |
Dupont Pharmaceuticals Company |
Tetrazine bicyclic compounds
|
|
US6124289A
(en)
*
|
1996-07-24 |
2000-09-26 |
Dupont Pharmaceuticals Co. |
Azolo triazines and pyrimidines
|
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
|
JP2001511813A
(ja)
|
1997-02-18 |
2001-08-14 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
|
|
JP2002501493A
(ja)
|
1997-04-22 |
2002-01-15 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Ｃｒｆアンタゴニストのチオフェノピリジン類
|
|
PL337888A1
(en)
|
1997-07-03 |
2000-09-11 |
Du Pont Pharm Co |
Imidazoprimidines and imidazopyridines for use in treating neurological disorders
|
|
EP1049699B1
(en)
*
|
1998-01-28 |
2004-04-21 |
Bristol-Myers Squibb Pharma Company |
Pyrazolotriazines as crf antagonists
|
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
|
US6472402B1
(en)
|
1998-04-02 |
2002-10-29 |
Neurogen Corporation |
Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
|
|
JP2002510686A
(ja)
|
1998-04-02 |
2002-04-09 |
ニューロゲン コーポレイション |
アミノアルキルで置換された５，６，７，８−テトラヒドロ−９Ｈ−ピリジノ［２，３−ｂ］インドール及び５，６，７，８−テトラヒドロ−９Ｈピリミジノ［４，５−Ｂ］インドール誘導体：ＣＲＦ１特異的配位子
|
|
WO1999051608A1
(en)
*
|
1998-04-03 |
1999-10-14 |
Du Pont Pharmaceuticals Company |
THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
|
|
US6194574B1
(en)
|
1998-06-09 |
2001-02-27 |
Neurogen Corporation |
Pyrido[2,3-b]indolizine derivatives and aza analogues thereof: CRF1 specific ligands
|
|
US6509338B1
(en)
|
1998-06-22 |
2003-01-21 |
Bristol-Myers Squibb Company |
Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
|
|
CA2339188A1
(en)
|
1998-08-21 |
2000-03-02 |
Dupont Pharmaceuticals Company |
Isoxazolo¬4,5-d|pyrimidines as crf antagonists
|
|
US6531475B1
(en)
*
|
1998-11-12 |
2003-03-11 |
Neurocrine Biosciences, Inc. |
CRF receptor antagonists and methods relating thereto
|
|
EP1129096B1
(en)
|
1998-11-12 |
2003-05-21 |
Neurocrine Biosciences, Inc. |
Crf receptor antagonists and methods relating thereto
|
|
IL142893A0
(en)
*
|
1998-11-12 |
2002-04-21 |
Neurocrine Biosciences Inc |
Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
|
|
AU2321000A
(en)
*
|
1999-01-29 |
2000-08-18 |
Sumitomo Chemical Company, Limited |
Fat accumulation inhibitory agents
|
|
EP1040831A3
(en)
*
|
1999-04-02 |
2003-05-02 |
Pfizer Products Inc. |
Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
|
|
WO2000059908A2
(en)
*
|
1999-04-06 |
2000-10-12 |
Du Pont Pharmaceuticals Company |
Pyrazolopyrimidines as crf antagonists
|
|
WO2000059907A2
(en)
|
1999-04-06 |
2000-10-12 |
Du Pont Pharmaceuticals Company |
Pyrazolotriazines as crf antagonists
|
|
EP1669071B1
(en)
*
|
1999-05-21 |
2009-07-22 |
Bristol-Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
|
US6982265B1
(en)
|
1999-05-21 |
2006-01-03 |
Bristol Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
|
US6432989B1
(en)
|
1999-08-27 |
2002-08-13 |
Pfizer Inc |
Use of CRF antagonists to treat circadian rhythm disorders
|
|
IL148903A0
(en)
|
1999-09-30 |
2002-09-12 |
Neurogen Corp |
Certain alkylene diamine-substituted heterocycles
|
|
JP2003510325A
(ja)
|
1999-09-30 |
2003-03-18 |
ニューロジェン・コーポレーション |
ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
|
|
SE9903544D0
(sv)
*
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
|
CO5271670A1
(es)
|
1999-10-29 |
2003-04-30 |
Pfizer Prod Inc |
Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
|
|
TWI271406B
(en)
|
1999-12-13 |
2007-01-21 |
Eisai Co Ltd |
Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
|
|
GB2359078A
(en)
|
2000-02-11 |
2001-08-15 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
GB2359081A
(en)
*
|
2000-02-11 |
2001-08-15 |
Astrazeneca Uk Ltd |
Pharmaceutically active thiazolopyrimidines
|
|
DE60101372T2
(de)
*
|
2000-02-11 |
2004-10-14 |
Astrazeneca Ab |
Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
|
|
CA2398956A1
(en)
*
|
2000-02-14 |
2001-08-16 |
Japan Tobacco Inc. |
A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
|
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
EP1149583A3
(en)
*
|
2000-04-13 |
2001-11-14 |
Pfizer Products Inc. |
Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
|
|
WO2001087892A1
(en)
*
|
2000-05-18 |
2001-11-22 |
Neurocrine Biosciences, Inc. |
Crf receptor antagonists
|
|
JP2004503553A
(ja)
|
2000-06-14 |
2004-02-05 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
６，５−縮合二環式複素環
|
|
US6630476B2
(en)
|
2000-07-07 |
2003-10-07 |
Bristol-Myers Squibb Pharma Company |
Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
|
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
DE60130924T2
(de)
|
2000-12-28 |
2008-07-17 |
Ono Pharmaceutical Co. Ltd. |
Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist
|
|
GB0100624D0
(en)
|
2001-01-10 |
2001-02-21 |
Vernalis Res Ltd |
Chemical compounds VII
|
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
|
BR0208357A
(pt)
*
|
2001-03-13 |
2004-06-29 |
Bristol Myers Squibb Pharma Co |
Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
|
|
SE0101322D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
Novel compounds
|
|
WO2002088121A1
(en)
|
2001-04-27 |
2002-11-07 |
Eisai Co., Ltd. |
Pyrazolo[1,5-a]pyridines and medicines containing the same
|
|
JP2004530702A
(ja)
|
2001-05-21 |
2004-10-07 |
ニューロクライン バイオサイエンシーズ， インコーポレイテッド |
Ｃｒｆ受容体アンタゴニストとしてのトリ−およびテトラアザ−アセナフチレン誘導体
|
|
GB0117396D0
(en)
|
2001-07-17 |
2001-09-05 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
|
TW200300350A
(en)
|
2001-11-14 |
2003-06-01 |
Bristol Myers Squibb Co |
C-5 modified indazolylpyrrolotriazines
|
|
AU2003217712A1
(en)
|
2002-03-07 |
2003-09-22 |
Smithkline Beecham Corporation |
Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
|
|
ATE478872T1
(de)
*
|
2002-03-28 |
2010-09-15 |
Ustav Ex Botan Av Cr V V I I O |
Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
|
|
US7119200B2
(en)
*
|
2002-09-04 |
2006-10-10 |
Schering Corporation |
Pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
|
AR041470A1
(es)
*
|
2002-10-17 |
2005-05-18 |
Upjohn Co |
Compuestos de pirrolo (1,2 - b) piridazina y sus usos
|
|
US7176216B2
(en)
|
2002-10-22 |
2007-02-13 |
Eisai Co., Ltd. |
7-phenylpyrazolopyridine compounds
|
|
SI1555265T1
(sl)
|
2002-10-22 |
2009-06-30 |
Eisai R&D Man Co Ltd |
7-fenil pirazolopiridinske spojine
|
|
TW200420565A
(en)
|
2002-12-13 |
2004-10-16 |
Bristol Myers Squibb Co |
C-6 modified indazolylpyrrolotriazines
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
KR101312736B1
(ko)
*
|
2003-02-27 |
2013-09-27 |
팔라우 파르마 에스에이 |
피라졸로피리딘 유도체
|
|
US7041671B2
(en)
*
|
2003-04-02 |
2006-05-09 |
Pfizer Inc |
Pyrrolo[1,2-b]pyridazine compounds and their uses
|
|
US7056920B2
(en)
|
2003-04-04 |
2006-06-06 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
|
US7034023B2
(en)
|
2003-04-04 |
2006-04-25 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
|
GB0308208D0
(en)
|
2003-04-09 |
2003-05-14 |
Glaxo Group Ltd |
Chemical compounds
|
|
JP2006523675A
(ja)
*
|
2003-04-15 |
2006-10-19 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ピロロ［１，２−ｂ］ピリダジン化合物及びそれらの使用
|
|
EA008596B1
(ru)
|
2003-04-29 |
2007-06-29 |
Пфайзер Инк. |
5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
|
|
WO2004099213A2
(en)
*
|
2003-05-07 |
2004-11-18 |
Pharmacia & Upjohn Company Llc |
Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
|
|
WO2004110454A1
(ja)
*
|
2003-06-13 |
2004-12-23 |
Ishihara Sangyo Kaisha, Ltd. |
アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
|
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
US7132426B2
(en)
|
2003-07-14 |
2006-11-07 |
Arena Pharmaceuticals, Inc. |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
|
US20050113379A1
(en)
*
|
2003-09-05 |
2005-05-26 |
Ping Ge |
Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
|
|
US7208596B2
(en)
|
2003-11-25 |
2007-04-24 |
Bristol-Myers Squibb Pharma Company |
Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
|
|
US7153961B2
(en)
|
2003-11-25 |
2006-12-26 |
Bristol-Myers Squibb Pharma Co. |
Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
|
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
|
US7102001B2
(en)
|
2003-12-12 |
2006-09-05 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine
|
|
CA2550948A1
(en)
|
2003-12-22 |
2005-07-14 |
Sb Pharmco Puerto Rico Inc. |
Crf receptor antagonists and methods relating thereto
|
|
MY145634A
(en)
|
2003-12-29 |
2012-03-15 |
Bristol Myers Squibb Co |
Pyrrolotriazine compounds as kinase inhibitors
|
|
US7064203B2
(en)
|
2003-12-29 |
2006-06-20 |
Bristol Myers Squibb Company |
Di-substituted pyrrolotriazine compounds
|
|
RU2006128580A
(ru)
|
2004-01-06 |
2008-02-20 |
Тайсо Фармасьютикал Ко., Лтд. (Jp) |
Производные тиенопиримидина и тиенопиридина, замещенные циклической аминогруппой
|
|
EP1706410A2
(en)
*
|
2004-01-06 |
2006-10-04 |
Taisho Pharmaceutical Co., Ltd |
Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists
|
|
HRP20130971T1
(hr)
|
2004-02-20 |
2013-11-08 |
Boehringer Ingelheim International Gmbh |
Inhibitori virusne polimeraze
|
|
US7102002B2
(en)
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US7102003B2
(en)
|
2004-07-01 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
DE602005014375D1
(de)
*
|
2004-10-19 |
2009-06-18 |
Neurocrine Biosciences Inc |
Crf-rezeptor-antagonisten und zugehörige verfahren
|
|
GB0519957D0
(en)
|
2005-09-30 |
2005-11-09 |
Sb Pharmco Inc |
Chemical compound
|
|
US7151176B2
(en)
|
2004-10-21 |
2006-12-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
|
JP5089395B2
(ja)
|
2004-10-29 |
2012-12-05 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
治療用フロピリミジンおよびチエノピリミジン
|
|
US7674822B2
(en)
|
2004-11-24 |
2010-03-09 |
Wyeth |
PTP1b inhibitors
|
|
EP1863500A2
(en)
|
2005-03-29 |
2007-12-12 |
Biocryst Pharmaceuticals, Inc. |
Hepatitis c therapies
|
|
EP1903045A1
(en)
*
|
2005-05-27 |
2008-03-26 |
Mitsubishi Tanabe Pharma Corporation |
Pyrazolopyrimidine derivative
|
|
TW200740820A
(en)
|
2005-07-05 |
2007-11-01 |
Takeda Pharmaceuticals Co |
Fused heterocyclic derivatives and use thereof
|
|
EP1915377A1
(en)
|
2005-07-22 |
2008-04-30 |
Sunesis Pharmaceuticals, Inc. |
Pyrazolo pyrimidines useful as aurora kinase inhibitors
|
|
US20070078136A1
(en)
|
2005-09-22 |
2007-04-05 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
|
US7514435B2
(en)
|
2005-11-18 |
2009-04-07 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
US8063208B2
(en)
|
2006-02-16 |
2011-11-22 |
Bristol-Myers Squibb Company |
Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
|
|
AU2007297481B2
(en)
|
2006-09-20 |
2012-03-08 |
Eli Lilly And Company |
Thiophene pyrazolopyrimidine compounds
|
|
EP2094709B1
(en)
|
2006-09-20 |
2010-09-15 |
Eli Lilly And Company |
Thiazole pyrazolopyrimidines as crf1 receptor antagonists
|
|
ATE543819T1
(de)
|
2006-10-19 |
2012-02-15 |
Signal Pharm Llc |
Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
|
|
NZ586662A
(en)
|
2007-12-19 |
2012-08-31 |
Vertex Pharma |
PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
|
|
US8394823B2
(en)
|
2008-04-11 |
2013-03-12 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as DGAT1 inhibitors
|
|
WO2009126624A1
(en)
|
2008-04-11 |
2009-10-15 |
Bristol-Myers Squibb Company |
Triazolo compounds useful as dgat1 inhibitors
|
|
RS52561B
(sr)
|
2008-04-15 |
2013-04-30 |
Eisai R&D Management Co., Ltd. |
Jedinjenje 3-fenilpirazolo[5,1-b]tiazol
|
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
|
TWI491610B
(zh)
|
2008-10-09 |
2015-07-11 |
必治妥美雅史谷比公司 |
作為激酶抑制劑之咪唑并嗒腈
|
|
AR078521A1
(es)
|
2009-10-08 |
2011-11-16 |
Eisai R&D Man Co Ltd |
Compuesto pirazolotiazol
|
|
PH12012501662A1
(en)
*
|
2010-02-18 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Triazolo [4,5 - b] pyridin derivatives
|
|
US8912184B1
(en)
|
2010-03-01 |
2014-12-16 |
Alzheimer's Institute Of America, Inc. |
Therapeutic and diagnostic methods
|
|
EP2558469B1
(en)
*
|
2010-04-16 |
2014-08-13 |
Abbvie Inc. |
Pyrrolopyrazinone inhibitors of kinases
|
|
JP5583845B2
(ja)
|
2010-04-28 |
2014-09-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
イミダゾピリダジニル化合物および癌に対するそれらの使用
|
|
TWI541243B
(zh)
|
2010-09-10 |
2016-07-11 |
拜耳知識產權公司 |
經取代咪唑并嗒
|
|
PH12013500547A1
(en)
|
2010-09-22 |
2013-06-10 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
US9266880B2
(en)
|
2010-11-12 |
2016-02-23 |
Bristol-Myers Squibb Company |
Substituted azaindazole compounds
|
|
US9284317B2
(en)
|
2010-12-17 |
2016-03-15 |
Bayer Intellectual Property Gmbh |
Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
|
|
JP5822944B2
(ja)
|
2010-12-17 |
2015-11-25 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン
|
|
CN103415518A
(zh)
|
2010-12-17 |
2013-11-27 |
拜耳知识产权有限责任公司 |
在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
|
|
HUE055286T2
(hu)
|
2011-04-08 |
2021-11-29 |
Janssen Sciences Ireland Unlimited Co |
Pirimidinszármazékok vírusfertõzések kezelésére
|
|
WO2012149157A2
(en)
*
|
2011-04-26 |
2012-11-01 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
US8969586B2
(en)
|
2011-09-27 |
2015-03-03 |
Bristol-Myers Squibb Company |
Substituted bicyclic heteroaryl compounds
|
|
RS57851B1
(sr)
|
2011-11-09 |
2018-12-31 |
Janssen Sciences Ireland Uc |
Purinski derivati za tretman viralnih infekcija
|
|
CN104284896B
(zh)
|
2012-03-14 |
2016-06-01 |
拜耳知识产权有限责任公司 |
取代的咪唑并哒嗪
|
|
WO2014009305A1
(en)
*
|
2012-07-09 |
2014-01-16 |
Janssen Pharmaceutica Nv |
Inhibitors of phosphodiesterase 10 enzyme
|
|
CA2874800C
(en)
|
2012-07-13 |
2021-04-06 |
Janssen R&D Ireland |
Macrocyclic purines for the treatment of viral infections
|
|
WO2014020041A1
(en)
|
2012-08-02 |
2014-02-06 |
Bayer Pharma Aktiengesellschaft |
Combinations for the treatment of cancer
|
|
LT2906563T
(lt)
|
2012-10-10 |
2018-06-11 |
Janssen Sciences Ireland Uc |
Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui
|
|
WO2014066795A1
(en)
|
2012-10-25 |
2014-05-01 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
WO2014066743A1
(en)
|
2012-10-25 |
2014-05-01 |
Bioenergenix |
Heterocyclic compounds for the inhibition of pask
|
|
EP2925729B1
(en)
|
2012-11-16 |
2017-10-18 |
Janssen Sciences Ireland UC |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
|
WO2014128189A1
(en)
|
2013-02-21 |
2014-08-28 |
Janssen R&D Ireland |
2-aminopyrimidine derivatives for the treatment of viral infections
|
|
WO2014139326A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
AU2014242954B2
(en)
|
2013-03-29 |
2018-03-15 |
Janssen Sciences Ireland Uc |
Macrocyclic deaza-purinones for the treatment of viral infections
|
|
SG11201509520QA
(en)
|
2013-05-24 |
2015-12-30 |
Janssen Sciences Ireland Uc |
Pyridone derivatives for the treatment of viral infections and further diseases
|
|
RS56034B1
(sr)
|
2013-06-11 |
2017-09-29 |
Bayer Pharma AG |
Derivati prolekova supstituisanih triazolopiridina
|
|
BR112015032546B1
(pt)
|
2013-06-27 |
2022-05-17 |
Janssen Sciences Ireland Uc |
Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças
|
|
KR102322425B1
(ko)
|
2013-07-30 |
2021-11-05 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
|
|
EP2940022B1
(en)
*
|
2014-04-30 |
2020-09-02 |
Masarykova Univerzita |
Furopyridines as inhibitors of protein kinases
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
RU2699568C2
(ru)
*
|
2015-12-21 |
2019-09-06 |
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" |
Лиганды транслокаторного белка TSPO, обладающие антидепрессивной и ноотропной активностью
|
|
AU2017289418B2
(en)
|
2016-07-01 |
2021-06-03 |
Janssen Sciences Ireland Unlimited Company |
Dihydropyranopyrimidines for the treatment of viral infections
|
|
JP7274415B2
(ja)
|
2016-09-29 |
2023-05-16 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
|
|
CN118845788A
(zh)
|
2017-08-14 |
2024-10-29 |
云杉生物科学公司 |
促肾上腺皮质激素释放因子受体拮抗剂
|
|
TW202415645A
(zh)
|
2018-03-01 |
2024-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
EP4438124A3
(en)
|
2018-04-27 |
2024-12-18 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
CN108812546A
(zh)
*
|
2018-09-07 |
2018-11-16 |
四川省草原科学研究院 |
适于青藏高原地区牦牛运输减少应激的药物及使用方法
|
|
BR112023002497A2
(pt)
|
2020-08-12 |
2023-05-02 |
Spruce Biosciences Inc |
Métodos e composições para tratamento da síndrome dos ovários policísticos
|
|
US11708372B2
(en)
|
2021-11-19 |
2023-07-25 |
Spruce Biosciences, Inc. |
Crystalline composition of tildacerfont and methods of use and preparation thereof
|